BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Prototypes - ECPv6.7.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Prototypes
X-ORIGINAL-URL:https://prototypes.tristar.solutions
X-WR-CALDESC:Events for Prototypes
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20210314T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20211107T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20210614T101500
DTEND;TZID=America/Chicago:20210614T110000
DTSTAMP:20260620T030512
CREATED:20210211T222107Z
LAST-MODIFIED:20210420T191209Z
UID:219-1623665700-1623668400@prototypes.tristar.solutions
SUMMARY:VASCEPA® (icosapent ethyl)—Elevating the Standard of Care (This Product Theater is Presented Live)
DESCRIPTION:There is an urgency to treat Persistent Cardiovascular Risk (P-CVR) as it remains high despite statin-based standard-of-care therapy in patients with elevated triglycerides. In this program\, we will review data from a practice changing trial that provides a new therapeutic option to elevate the current standard of care.Presenter: Yehuda Handelsman\, MD\, FACP\, FNLA\, FASPC\, MACE EndocrinologistMedical Director & Principal InvestigatorMetabolic Institute of AmericaTarzana\, CA
URL:https://prototypes.tristar.solutions/event/sl-test-006/
CATEGORIES:Product Theaters
LOCATION:https://youtu.be/ScMzIvxBSi4
END:VEVENT
END:VCALENDAR